Compare Davita Inc (DVA) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Prospect Capital Corporation — how do they compare? Davita Inc trades at $178.24 (market cap $11.29B), while Prospect Capital Corporation trades at $1.8 (market cap $974.22M). The key difference: Davita Inc is far larger — about 11.6× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 23.01% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Prospect Capital Corporation for 78 Days on average.
| DVA | PSEC | |
|---|---|---|
Market Cap | $11.29B | $974.22M |
Volume | 582,204 | 5,779,996 |
Sector | Health | Financials |
52-Week High | $240.96 | $3.05 |
52-Week Low | $103.87 | $1.82 |
Typical Hold Time | 113 Days | 78 Days |
Enterprise Value | $24.01B | $2.73B |
Dividend Yield | — | 23.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
PSEC trades at $1.84, up 0.55% on the day, with a bearish technical signal from moving averages despite bullish RSI readings. The company reported negative revenue and net income for 2025, though recent quarterly EPS have beaten expectations. Dividend distributions continue, but analyst consensus is mixed with a majority hold rating. Recent news highlights distribution announcements and management commentary on lower middle-market opportunities.
The outlook is cautious; PSEC's high yield and low P/B ratio present value, but persistent negative cash flow, volatile profitability, and a bearish technical trend pose significant risks. Investor sentiment is divided, with concerns over NAV erosion and portfolio contraction offset by income-focused appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
